Abraham Ceesay, Rapport Therapeutics CEO
June 7, 2024 11:27 AM EDT
R&D

Neu­ro­science com­pa­ny Rap­port Ther­a­peu­tics lists on Nas­daq

Lei Lei Wu

News Reporter

Rap­port Ther­a­peu­tics ex­pects to raise $154 mil­lion from its ini­tial pub­lic of­fer­ing and a con­cur­rent stock sale to pri­vate in­vestors, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

A service from the Financial Times